Hyaluronic Acid (HA) Viscosupplementation on Synovial Fluid Inflammation in Knee Osteoarthritis: A Pilot Study

Heather K. Vincent*,1, Susan S. Percival2, Bryan P. Conrad1, Amanda N. Seay1, Cindy Montero1 and Kevin R. Vincent1

1Department of Orthopaedics and Rehabilitation, Interdisciplinary Center for Musculoskeletal Training and Research, 2Department of Food Sciences and Nutrition, University of Florida, Gainesville, FL 32608, USA

Abstract: Objective: This study examined the changes in synovial fluid levels of cytokines, oxidative stress and viscosity six months after intraarticular hyaluronic acid (HA) treatment in adults and elderly adults with knee osteoarthritis (OA).

Design: This was a prospective, repeated-measures study design in which patients with knee OA were administered 1% sodium hyaluronate. Patients (N=28) were stratified by age (adults, 50-64 years and elderly adults, ≥65 years). Ambulatory knee pain values and self-reported physical activity were collected at baseline and month six.

Materials and Methods: Knee synovial fluid aspirates were collected at baseline and at six months. Fluid samples were analyzed for pro-inflammatory cytokines (interleukins 1, 6,8,12, tumor necrosis factor-α, monocyte chemotactic protein), anti-inflammatory cytokines (interleukins 4, 10 13), oxidative stress (4-hydroxynonenal) and viscosity at two different physiological shear speeds 2.5Hz and 5Hz.

Results: HA improved ambulatory knee pain in adults and elderly groups by month six, but adults reported less knee pain-related interference with participation in exercise than elderly adults. A greater reduction in TNF-α occurred in adults compared to elderly adults (-95.8% ± 7.1% vs 19.2% ± 83.8%, respectively; p=0.044). Fluid tended to improve at both shear speeds in adults compared to the elderly adults. The reduction in pain severity correlated with the change in IL-1β levels by month six (r= -.566; p=.044).

Conclusion: Reduction of knee pain might be due to improvements in synovial fluid viscosity and inflammation. Cartilage preservation may be dependent on how cytokine, oxidative stress profiles and viscosity change over time.

Keywords: Cytokine, inflammation, knee, osteoarthritis, pain, viscosity.

INTRODUCTION

Knee osteoarthritis (OA) may be triggered by excessive joint forces, defects to the articular cartilage or subchondral bone. Chondrocytes become metabolically active and initiate inflammatory processes that degrade articular cartilage and subchondral bone. Chondrocytes secrete several inflammatory cytokines that work synergistically to stimulate synthesis of enzymes that break down cartilage. Key cytokines include interleukin-1 (IL-1β), tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) [1]. IL-1β and TNF-α are commonly increased in inflamed joints, and these cytokines activate other inflammatory chemokines such as monocyte chemotactic proteins and others [2]. Hence, inflammation is a critical modifier of joint disease and progression.

Intriguing, but very limited evidence also suggests a role for oxidative stress-related degradation processes in human OA [3]. Oxidative stress represents the imbalance between endogenous antioxidant defenses and the free radical induced pro-oxidant processes that result in oxidative modification of molecules. Relevant to osteoarthritis, byproducts of lipid oxidation such as 4-hydroxynonenal (4-HNE) induce cell damage and death of chondrocytes [4, 5]. An imbalance of antioxidant defenses relative to oxidative processes has been shown to exist in human OA [3, 6]. The levels of oxidatively damaged byproducts such as lipid peroxides, are high in synovial fluid in patients with OA [3, 6]. These adverse changes correspond with cartilage breakdown.

Normally, synovial fluid contains high levels of hyaluronic acid (HA) that help to maintain high fluid viscosity and the normal integrity of the joint by attenuating inflammation and preserving the normal cartilaginous matrix. In OA, the synovial fluid viscosity and elasticity are decreased [7, 8]. HA is a polysaccharide produced by the chondrocytes and synoviocytes. While HA may help to lubricate and cushion the joint [9], it can help maintain cartilage matrix and minimize inflammation. In OA, the molecular weight and concentration of HA are reduced [10], thereby lowering fluid viscosity and elasticity. Protection against articular injury is compromised and OA damage ensues. In vitro data suggest supplemental HA can suppress IL-1β production [11], and may increase synovial fluid viscosity [10]. We hypothesize that intraarticular HA can suppress not only IL-1β, but also can reduce the overall
inflammatory cytokine response in human OA. Clinical practice and anecdotal evidence suggest that HA may be more beneficial in mild to moderate OA [12]. However, most of evidence on disease severity and age has been derived from animal models of OA [13, 14]. Human studies have found that patients >60 years with higher disease severity responded better to HA than counterparts younger than 60 years [15]. Identification of the patient type with better responsiveness to HA would be an important next step in optimizing OA treatment for this clinical population.

Although published data on this topic are limited, we surmise that HA may be important in suppressing oxidative stress by reducing toxic oxidative byproducts [16] such as 4-HNE in the synovium. This suppression might be related to improvements in knee pain symptoms, improvements in physical activity and synovial fluid viscosity. These issues remain unclear at the present time. Therefore, the primary purpose of this study was to compare the six month changes in synovial fluid cytokine levels, 4-HNE and fluid viscosity after an intraarticular HA injection series in adults and elderly adults with knee OA. The secondary purpose was to determine whether there were improvements in knee pain and physical activity levels. This information will enhance our understanding of the mechanisms of joint repair and functional outcomes with intraarticular HA.

MATERIALS AND METHODOLOGY

Study Design

This was a prospective, repeated-measures study design in which the effects of a HA viscosupplement injection series on inflammatory parameters and viscosity of knee synovial fluid aspirates were examined. Pre-injection and month six levels of synovial fluid biomarker levels (inflammatory, oxidative stress) and fluid viscosity were measured. This study was approved by the University of Florida Institutional Review Board (UFIRB), and all procedures on human subjects were conducted in accordance with the Helsinki Declaration of 1975, as revised in 2000. All patients read, understood and signed an informed consent document.

Patients

Patients (N=28) with chronic knee OA were recruited from the UF Orthopaedics Clinics. The inclusion criteria were a diagnosis of knee OA, degenerative joint disease or joint degeneration (these diagnoses were primary or secondary due to trauma or a sports injury). Patients had to be fully cognizant of all study procedures and willing to withhold taking any new knee OA medications for six months. The exclusion criteria were: allergic to hyalurans, currently experiencing a knee infection or skin infection around the injection site, other current skin disease and wheelchair dependent. Patients were stratified into adults (50-64 years) and elderly adults (≥65 years). The age cutoffs were chosen to represent the age at which OA becomes one of the top co-morbidities in men (50 years) [17], and a general accepted definition of elderly (≥65 years). A group of controls was not approved for this study due to the elevated risk to benefit ratio of obtaining intraarticular fluid samples in persons not receiving a treatment. Weight bearing anteroposterior knee radiographs were classified according to the Kellgren–Lawrence (KL) radiographic rating scale [18] by the study physician (KRV). All patients read, understood and signed a UF IRB approved informed consent form. The selection of 28 participants was based on the ability to detect a minimal clinically relevant reduction in knee pain severity of 30% by month six [19], and a ~50% decrease in IL-1β similar to that observed in HA injection in other arthritic joints [20].

Patient History and Physical Activity Patterns

All patients completed a specific health history questionnaire which included demographic data, current and past medical issues, current medications, knee OA history and current medications. The current physical activity patterns were captured by documenting the type of exercise, the number of weekly activity sessions, and the average session duration in block levels. The duration block levels were: 1) 10-15 min, 2) 15-30 min, 3) 30-45 min, 4) 45min-1 hr and 5) ≥1 hour. For example, a participant who walked three times a week for 45 minutes would have the exercise pattern entered into the statistical program as: walking (activity type), 3 (frequency per week), block 3 (duration of walking). Knee pain severity was self-assessed during walking activity using an 11 point numerical pain rating scale (NRSpain) with terminal anchors (0 = “no pain”; 10 = “worst possible pain”). The NRSpain is an accepted outcome measure for chronic pain conditions, as described in the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials [21]. This measurement is reliable and valid [22] for assessing pain intensity.

Intraarticular Injection Procedure for Hyaluronic Acid

The patient sat with the knee(s) flexed at 90°. The injection site was cleansed with chlorhexidine, and local anesthesia was provided to the pathway for the injection using three mL of 1% lidocaine. An anteromedial or lateral approach was performed for these injections. A 20g needle with a 20 ml syringe was utilized to withdraw synovial fluid aspirate to be used for subsequent analysis. The aspirate was immediately aliquoted and frozen at -70°C. A preloaded syringe of two ml of viscosupplement (Euflexxa®) was then delivered through a 20-gauge 1/2 inch needle using the anteromedial or lateral approach. The patients were observed for 15 minutes post-procedure. Two more injections were provided to each patient at weekly intervals for a total of three injections.

Synovial Aspirate Analyses

A series of cytokines and oxidative stress measurements and viscosity measures were collected from synovial fluid aspirates at baseline and month six.

Cytokine Assessments

A Milliplex MAP kit of Human Cytokines/Chemokines (cat #s HCYTOMAG-60K, 60K-PX29, 30, 39, 42; Millipore Corp.; Billerica, MA) was used for the simultaneous quantification of several cytokines. These included inflammatory interleukins 1β, 6, 8, 12, monocyte chemotactic protein-1 (MCP-1), granulocyte macrophage stimulating factor (GM-CSF), interferon gamma (IFNγ)[2]. Anti-inflammatory cytokines included interleukins 4, 10 and 13., fluid mixtures of color coded microspheres with two
fluorescent dyes were created and coated with antibodies specific to the cytokines measured. The synovial fluid samples were mixed with the dyed microspheres, and the cytokines were captured. The mixture was exposed to Streptavidin PE conjugate and passed through a laser. The cytokine levels were quantified by the amount of fluorescence of the sample using a multiplex plate reader (Luminex, Austin TX). Samples were run in duplicate; if one sample was markedly different than the other, a third sample was analyzed.

**Synovial Fluid 4-Hydroxynonenal (4-HNE) Content**

4-HNE may be involved in the pathogenesis of osteoarthritis via cartilage breakdown [23]. 4-HNE content was determined using an enzyme linked immunosorbent assay (OxiSelect ELISA, Cell Biolabs, Inc; San Diego CA; cat STA-338-5). Samples were run in duplicate; if one sample was markedly different than the other, a third sample was analyzed.

**Viscosity Assessment**

To determine whether the viscous properties of the synovial fluid aspirates changed from baseline to month six, a viscometer was used (Brookfield cone plate viscometer; Middleboro, MA; cp-52 cone, 3° angle). A 0.5mL sample of synovial fluid was placed into the viscometer, and a torque meter was driven at discrete rotational speeds. The internal measuring system was comprised of a spring mechanism connected to a rotating cone that senses resistance to rotation caused by the synovial samples. The resistance to rotation of the cone is proportional to the shear stress in the fluid; the reading was converted to centipoise units (cP). A circulating water bath maintained all sample temperatures at 25° C. The fluid viscosity was assessed at two different shear speeds (2.5Hz and 5Hz) to simulate how fluid might behave during stresses experienced during normal physiological activities such as walking [24, 25].

**Statistics**

Data analysis was performed using the Statistical Package for the Social Sciences (SPSS, v. 20). Descriptive measures and frequencies were compared at baseline between the two age groups. Repeated measures analysis of variance (ANOVA) were performed on the biochemical and viscosity variables, where age group was the between factor (adults, elderly adults) and the within group factor was time (baseline, month 6). Greenhouse-Geisser corrections were used. Change scores in the cytokine levels and 4-HNE were determined (change from baseline to month six) and compared between age brackets using independent samples t-tests. These same analyses were performed using the KL OA staging (stage II, II, IV) as between group factors to determine the effect of OA stage on the study outcomes. Non-parametric tests (Mann Whitney U tests) were used to determine whether comparisons were found to be significant, and simple main effects were analyzed using a one way AONVA. Significance was established at \( p \leq 0.05 \) for all analyses.

**RESULTS**

**Patients**

Participant characteristics are shown in Table 1. By month six, two patients, one from each age group, had opted for knee replacement surgery because the pain did not improve. The six month data represent the patients who completed the study. Among all patients, there was an average reduction in pain severity from 7.8 ± 1.5 points to 3.8 ± 3.5 points (an average pain reduction of 51.2%; \( p=0.0001 \)). There were no adverse events to report.

| Table 1. Baseline Participant Characteristics. Values are Means ± SD, or % of the Group |
|-----------------------------------------|-----------------|-----------------|
| **Adults** (n=14) | **Elderly Adults** (n=14) |
| **Age** (years) | 57.3 ± 5.1 | 66.6 ± 1.3 |
| **Height** (cm) | 168 ± 8 | 167 ± 9 |
| **Weight** (kg) | 86 ± 16 | 86 ± 21 |
| **Body mass index** (kg/m²) | 30.1 ± 4.8 | 30.6 ± 5.1 |
| **Women** (%) | 57.1 | 57.1 |
| **Race** | | |
| Caucasian (%) | 92.9 | 78.6 |
| African-American (%) | 7.1 | 14.3 |
| Hispanic (%) | 0.0 | 7.1 |
| **Working Status** | | |
| Working (%) | 57.1 | 42.9 |
| Retired (%) | 7.1 | 50.0 * |
| Disabled (%) | 35.7 | 7.1 * |
| **Kellgren Lawrence OA Stage** | | |
| 2 (#) | 9 | 4 |
| 3 (#) | 3 | 6 |
| 4 (#) | 2 | 4 |
| Mean | 2.5 ± 0.8 | 3.0 ±0.8 |
| **Pain in both knees** (%) | 21.4 | 42.9 * |
| **Knee pain duration** (years) | 6.5 ± 9.3 | 11.1 ± 13.3 |
| **Knee pain grown worse over last 6 months** (yes, %) | 21.4 | 35.7 |
| **Medication Use for Pain** | | |
| NSAIDs (%) | 50.0 | 21.4 |
| Narcotics (%) | 35.7 | 71.4 * |
| Antidepressants (%) | 57.1 | 78.6 |

*Different at \( p<0.05 \).

**Knee Pain Symptoms**

The changes in knee pain symptoms related to physical activity are shown in Table 2. There was a significant group by time interaction, such that fewer adults reported that pain prevented exercise compared to elderly patients at six months (\( p<0.05 \)). There was no change in the number of weekly physical activity sessions. There was, however, a trend toward a significant group by time interaction for an increased session duration from baseline to month six (\( p=0.07 \)) suggestive of increased physical activity tolerance in the adults.
Table 2. Changes in Knee Symptoms and Relation to Physical Activity from Baseline to Month Six. Values are Means ± SD, or % of the Group

|                          | Adults    | Adults    | Elderly Adults | Elderly Adults |
|--------------------------|-----------|-----------|----------------|----------------|
|                          | Baseline  | Month Six | Baseline       | Month Six      |
| OA pain medication (#)   | 1.8 ± 1.5 | 0.9 ± 0.8 | 1.1 ± 0.7      | 1.2 ± 0.8      |
| Pain, walking (points) **| 8.0 ± 1.3 | 3.0 ± 5.0 | 7.6 ± 1.6      | 5.0 ± 4.0      |
| Pain prevents exercise (yes, %)* | 78.6 | 33.3 | 78.6 | 41.7 |

Physical Activity

|                          | Adults    | Adults    | Elderly Adults | Elderly Adults |
|--------------------------|-----------|-----------|----------------|----------------|
| AX≥ 3X/week (%)          | 50.0      | 66.6      | 42.8           | 46.2           |
| Session duration levela  | 1.3 ± 1.5 | 2.3 ± 1.4 | 1.4 ± 1.6      | 1.8 ± 1.5      |

Note: pain was assessed using a 0-10 Numerical pain rating scale. AX = aerobic exercise.

a Session duration: 1= 10-15 min, 2: 15-30 min, 3: 30-45 min, 4: 45min-1 hr and 5: ≥1 hour.

* The interaction of group by time, p<0.05; ** significant by time, p<0.05.

There was a trend for greater knee pain severity improvement in the stages II and III OA compared with stage IV OA (p=0.06); pain decreased by an average of 54% and 87% in patients with stages II and III compared to a 19% improvement in patients with stage IV OA.

Cytokine and 4-HNE

The baseline and six month cytokine levels are shown in Table 3.

Table 3. Cytokine Profiles from Baseline to Post-HA Viscosupplementation at Month Six. Values are Expressed in pg/ml and are Shown as Means ± SD

|                          | Adults    | Adults    | Elderly Adults | Elderly Adults |
|--------------------------|-----------|-----------|----------------|----------------|
|                          | Baseline  | Month 6   | Baseline       | Month 6        |
| Inflammatory             |           |           |                |                |
| IL-1β                    | 0.68 ± 0.192 | .298 ± 0.595 | .333 ± 0.763 | .107 ± 0.223  |
| IL-6                     | 429.5 ± 421.3 | 348.9 ± 372.8 | 187.7 ± 156.9 | 231.5 ± 257.4 |
| IL-8                     | 92.4 ± 73.0  | 67.1 ± 23.0 | 117.1 ± 106.7 | 162.8 ± 155.1 |
| IL-12                    | 2.29 ± 1.96  | 1.64 ± 1.68 | 0.81 ± 1.36   | 1.59 ± 1.95   |
| TNF-α*                   | 2.52 ± 3.09  | 1.33 ± 2.75 | 3.76 ± 3.71   | 5.38 ± 4.54   |
| MCP                      | 2797 ± 990   | 2189 ± 786  | 3117 ± 1397   | 3611 ± 1192   |
| Anti-Inflammatory        |           |           |                |                |
| IL-4                     | 2.8 ± 3.3   | 5.7 ± 8.6  | 10.2 ± 13.9   | 5.8 ± 6.7     |
| IL-10                    | 8.42 ± 6.47  | 6.39 ± 3.03 | 8.37 ± 5.04   | 8.40 ± 7.67   |
| IL-13                    | 505 ± 780   | 0.299 ± 0.745 | .606 ± 0.780 | 0.081 ± 0.229 |

Intxn= group by time interaction.
IL= interleukin; TNF= tumor necrosis factor; MCP = monocyte chemotactic protein.
*Change scores (difference between baseline and six months) between groups were different p<0.05.

While there were general reductions in the inflammatory cytokine levels in the adults compared to the elderly adults, these were not significant. There was a significant reduction in TNF-α from baseline to month six in adults compared with the elderly adults (p=0.044). Correlations revealed that the reduction in pain severity was moderately related with the change in IL-1β levels by month six (r= -.566; p=0.044). The changes in 4-HNE are shown in Fig. (1). While the increase in 4-HNE was less in adults compared to the elderly adults by month six (7% vs 21%), this difference was not found to be significant. Analyses revealed that none of the biochemical variables were different based on KL OA stage from baseline to month six (all p>0.05).

SYNOVIAL FLUID VISCOSITY

The change in viscosity between groups from baseline to month six tended to be greater in at the 2.5 Hz and 5Hz shear speed conditions in the adults compared to the elderly adults (Fig. 2a [p=0.07] and Fig. 2b [p=0.08]). Analyses revealed that the viscosity measures were not different based on KL OA stage from baseline to month six (all p>0.05).

DISCUSSION

The main purpose of this pilot study was to compare the changes in synovial fluid cytokine levels, 4-HNE and fluid viscosity by six months after an intraarticular HA injection series in adults and elderly adults. Values are means ± SD.

The main findings included a significant reduction in knee pain with HA by six months, and this was more improvement in pain severity than previously reported [26]. Pain reductions were accompanied by age-dependent improvements in fluid viscosity at higher shear speeds and a greater reduction in TNF-α in the elderly adults. Adults aged 50-64 reported less knee pain-related interference with participation in exercise than the elderly adults 65 years and older. While we did not find significant differences in pain relief among patients with different OA severity stages, we found a trend. The effects of HA likely involve a collective favorable improvement in pro- and anti-inflammatory cytokines, viscosity and oxidative damage in the synovial fluid.

Available comparative biochemical data have been derived largely from cell culture or animal studies.
Elderly patients >65 years at same time point, p=0.06.

six months after intra-articular HA injections in adults and elderly exposed to high molecular weight HA samples from patients with early stage OA (N=15) were Fibroblast like synoviocytes isolated from synovial fluid (a, b). Viscosity levels in knee synovial fluid before and six months after intra-articular HA injections in adults and elderly adults. Values are in centipoise (cP) in means ± SD. ^different than patients >65 years at same time point, p=0.06.

Fig. (2). (a, b). Viscosity levels in knee synovial fluid before and six months after intra-articular HA injections in adults and elderly adults. Values are in centipoise (cP) in means ± SD. ^different than patients >65 years at same time point, p=0.06.

Fibroblast like synoviocytes isolated from synovial fluid samples from patients with early stage OA (N=15) were exposed to high molecular weight HA in vitro [27]. HA down-regulated TNFα and IL-8 after 24 hours, indicating an anti-inflammatory effect. In degraded bovine cartilage tissue models in vitro, 1% HA solution promoted proteoglycan synthesis. The authors proposed that the superficial damaged synoviocytes permitted penetration of HA into the cartilage matrix for repair [28]. Rat models revealed that IL-1β induced chondrocyte apoptosis in vitro and found dose-dependent protection of HA against cell death [29]. In the rabbit knee OA model, HA treatment suppressed metalloproteinase and prostaglandin production over the short term, leading to better weight tolerance of the affected limb [30]. In patients with OA, HA has been shown to reduce synovial fluid IL-6 levels more than saline at one week (47% vs 33% reduction), but did not decrease TNF-α levels [31] as we observed in the present study. Two favorable trends in IL-4 elevations and monocyte chemotactic protein decreases occurred in the adults compared to the elderly. The different responses among studies may be due to the variations of HA preparations, the wide range of measurement time points after treatment, and the initial level of physical function.

Synovial fluid viscosity tended to increase by six months after HA treatment in both shear stress conditions in the adults compared to the elderly adults. Improvements in viscosity have been documented in OA (16%) [10], in persons with stage III knee gonarthrosis [32] and in rheumatoid arthritis [33] by three to six months post-injection. Our study expanded the viscosity measures to two different shear speeds to simulate different knee loading conditions. The significant increase in viscosity at higher shear speeds the adults concurrent with pain reduction suggests that either the quality of the synovial fluid by month six has improved or viscosity alters nociceptive nerve activity, or both. Animal models of knee inflammation indicate that intraarticular injections of elastoviscous HA can reduce movement-induced nociceptor impulse discharges [34] and reduce pain. There is the possibility that patients experience different HA effects depending on age or disease severity. For example, despite increases in inflammatory cytokines and 4-HNE and no change in viscosity, the elderly group reported lower knee pain severity. Perhaps this group experienced nociceptive change. These data indicate that adults had better quality synovial fluid by month six coupled with lower cytokine levels, and pain relief may have been mediated by different chemical pathways. These temporal patterns of pain change relative to physiological pathways in the knee joint need additional investigation.

STUDY LIMITATIONS AND FUTURE DIRECTIONS

Limitations to this study deserve comment. The lack of a formal control group was a limitation, but this was due to the higher risk to benefit ratio for persons who would not receive treatment. The study design used here has been used in a previous hyaluronon study in humans, in which sequential samples over time were collected to determine synovial fluid changes after intraarticular injection [35]. We believe that this study design provides valuable information regarding the individual responses to treatment. The relatively small sample size was related with variability in some of the synovial fluid biomarkers. We found intriguing trends in graded improvements in synovial fluid viscosity and knee pain symptoms based on age and OA stage. Larger studies are needed to confirm these findings. Previous cell culture work using human chondrocytes from patients with OA show variability in responsiveness to cytokines [35], indicating that there may be better responders to treatment. The fact that there was a greater percentage of persons with knee pain in both knees in the elderly adults than in the adults could influence biochemical responsiveness to the HA and might be a confounder. That is, a long exposure to OA over years could attenuate responsiveness of the cytokine pathways to treatment. The elderly adults had similar reductions in pain severity despite less change in viscosity, the elderly adults had better quality synovial fluid by month six coupled with lower cytokine levels, and pain relief may have been mediated by different chemical pathways. These temporal patterns of pain change relative to physiological pathways in the knee joint need additional investigation.

Because there were patterns of improvement in the adults (Table 3: less increase in 4-HNE, lower IL-6, IL-8, IL-12 and MCP values, higher IL-4 levels) suggests that there may be benefit to administering HA after less exposure time to OA. Adults may be more responsive to the HA than elderly adults. Comparative evidence on this topic is scarce, but animal model data support the notion that early treatment
with HA can limit future degenerative changes within the knee joint [36]. Additional studies are needed to determine whether there is an age-related threshold at which the HA improvements in pain and inflammation are minimal. We did not anticipate being unable to obtain synovial fluid aspirates in some patients by month six. This challenge has been reported in other HA studies [10, 33] and could signify that the components of the synovial fluid were being laid down as matrix in the damaged cartilage, and this warrants further investigation. Relationships between synovial fluid inflammation, oxidative stress, cartilage volume preservation and physical function should be examined across the age span to determine which patient populations may obtain the best benefit from HA treatment.

CONCLUSION

Compared to the elderly adults, adults reported less knee pain-related interference with participation in exercise by six months after HA treatment. Both age groups experienced less ambulatory pain by month six. Mitigation of pain might be due to an improvement in synovial fluid viscosity, reduction in inflammation. Longer prospective studies are needed to determine whether or not there is differential cartilage preservation based on age and OA stage and how cytokine, oxidative stress profiles and viscosity change over time.

CONFLICT OF INTEREST

This project was supported by an Investigator Initiated grant from Ferring Pharmaceuticals, 2010-2012 (HK Vincent, A Seay). The study sponsor had no involvement in any phase of the study conception, execution and manuscript preparation.

ACKNOWLEDGMENTS

The authors sincerely thank the contributions in data collection from Ms. Kelley Lamb, the equipment loan from Dr. Roger Son-Tay and the technical expertise of Ms. Joy Stanilika. The investigators also thank the study patients for their willingness to assist in this project.

REFERENCES

[1] Terrazanadeh J, Booya F, Root J. Cartilage metabolism in osteoarthritis and the influence of viscosupplementation and steroid: a review. Acta Radiol 2005; 46(3): 288-96.
[2] Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011; 7(1): 33-42.
[3] Regan EA, Bowler RP, Crapo JD. Joint fluid antioxidants are needed in osteoarthritic joints compared to joints with macroscopically intact cartilage and subacute injury. Oste Cart 2008; 16(4): 515-21.
[4] Shi Q, Vaillancourt F, Côté V, et al. Alterations of metabolic activity in human osteoarthritic osteoblasts by lipid peroxidation end product 4-hydroxynonenal. Arthritis Res Ther 2006; 8(6): R159.
[5] Vaillancourt F, Fahmi H, Shi Q, et al. 4-Hydroxynonenal induces apoptosis in human osteoarthritic chondrocytes: the protective role of glutathione-S-transferase. Arthritis Res Ther 2010; 12(5): R107.
[6] Alindag O, Erel O, Aksoy N, Selek S, Celik H, Karaoglanoglu M. Increased oxidative stress and its relation with collagen metabolism in knee osteoarthritis. Rheumatol Int 2007; 27(4): 339-44.
[7] Chen YQ, Chou PL, Cheng CY, et al. Microstructure of human synovial fluid of arthritis patients studied by diffusing wave spectroscopy. J Biophotonics 2012; 5(10): 777-84.
[8] Milas M, Rinaudo M, Roure I, Al-Assaf S, Phillips GO, Williams PA. Comparative rheological behavior of hyaluronan from bacterial and animal sources with cross-linked hyaluronan (hylan) in aqueous solution. Biopolymers 2001; 59(4): 191-204.
[9] Altman RD. Status of hyaluronan supplementation therapy in osteoarthritis. Curr Rheumatol Rep 2003; 5(1): 7-14.
[10] Bagga H, Burkhardt D, Sambrook P, March L. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol 2006; 33(5): 946-50.
[11] Takahashi K, Goomer RS, Harwood F, Kubo T, Hirasawa Y, Amiel D. The effect of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1 beta (IL-1 beta), and tissue inhibitor of the metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage 1999; 7(2): 182-90.
[12] Dagenais S. Intra-articular hyaluronic acid (viscosupplementation) for knee osteoarthritis. Issues Emerg Health Technol 2006; 94: 1-4.
[13] Marshall KW, Manolopoulos V, Mancer K, Staples J, Damyavanich A. Amelioration of disease severity by intraarticular hylan therapy in bilateral canine osteoarthritis. J Orthop Res 2000; 18(3): 416-25.
[14] Plaas A, Li J, Riesco J, Das R, Sandy JD, Harrison A. Intraarticular injection of hyaluronan prevents cartilage erosion, periarticular fibrosis and mechanical allodynia and normalizes stance time in murine knee osteoarthritis. Arthritis Res Ther 2011; 13(2): R46.
[15] Lohmander LS, Dalén N, Enlund G, H, et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Ann Rheum Dis 1996; 55(7): 424-31.
[16] Kalaci A, Yilmaz HR, Aslan B, Söüür S, Yanat AN, Uz E. Effects of hyaluronan on nitric oxide levels and superoxide dismutase activities in synovial fluid in knee osteoarthritis. Clin Rheumatol 2007; 26(8): 1306-11.
[17] Issa MM, Fenter TC, Black L, Grogg AL, Kruep EJ. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care 2006; 12(4 Suppl): S83-S89.
[18] Kellgren JH, Lawrence JS. Radiological assessment of osteoarthritis. Ann Rheum Dis 1957; 16(4): 494-502.
[19] Tubach F, Rayaud P, Baron G, F et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 2005; 64(1): 29-33.
[20] Hirota W. Intra-articular injection of hyaluronic acid reduces total amounts of leukotriene C4, 6-keto prostaglandin F1alpha, prostaglandin F2alpha and interleukin-1beta in synovial fluid of patients with internal derangement in disorders of the temporomandibular joint. Br J Oral Maxillofac Surg 1998; 36(1): 35-8.
[21] Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9(2): 105-21.
[22] Von Korff M, Jensen MP, Kolory W. Assessing global pain severity by self-report in clinical and health services research. Spine 2000; 25(24): 3140-51.
[23] Morquette B, Shi Q, Lavigne P, Ranger P, Fernandes JC, et al. Alterations of metabolic activity in human osteoarthritic cartilage and this warrants further investigation. Roles of hyaluronic acid. Arthritis Res Ther 2011; 13(2): R46.
[24] Balaazs EA. The Physical Properties of Synovial Fluid and the Special Role of Hyaluronic Acid. In: Helfet AJ, Ed. Disorders of the Knee. Philadelphia: JB Lippincott Company 1974; pp. 63-75.
[25] Mazzucco D, McKinley G, Scott RD, Spector M. Rheology of joint fluid in total knee arthroplasty patients. J Orthop Res 2006; 20(6): 1157-63.
[26] Altman RD, Rosen JE, Bloch DA, Hautoj HK, Korkor P. A double-blind, randomized, saline-controlled study of the efficacy and safety of UFELEXCA for treatment of pain osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). Semin Arthritis Rheum 2009; 39(1): 1-9.
[27] Wang CT, Lin TY, Chiu BL, Lin YH, Hou SM. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage 2006; 14(1): 1237-47.
[28] Fukuda K, Tan H, Takayama M, Kuman F, Saito T, Tanaka S. Hyaluronic acid increases proteoglycan synthesis in bovine cartilage.
articul cartilage in the presence of interleukin-1. J Pharmacol Exp Ther 1996; 277(3): 1672-5.

[29] Zhou PH, Liu SQ, Peng H. The effect of hyaluronic acid on IL-1beta-induced chondrocyte apoptosis in a rat model of osteoarthritis. J Orthop Res 2008; 26(12): 1638-43.

[30] Hashizume M, Koike N, Yoshida H, Suzuki M, Mihara M. High molecular weight hyaluronic acid relieved joint pain and prevented the progression of cartilage degeneration in a rabbit osteoarthritis model after onset of arthritis. Mod Rheumatol 2010; 20(5): 432-8.

[31] Sezgin M, Demirel AC, Karaca C, Ortancil O, Ulkar GB, Kanik A, Cakçi A. Does hyaluronan affect inflammatory cytokines in knee osteoarthritis? Rheumatol Int 2005; 25(4): 264-9.

[32] Grecomoro G, La Sala F, Francavilla G. Rheologic changes in the synovial fluid of patients with gonarthritis induced by intraarticular infiltration of hyaluronic acid. Int J Tissue React 2001; 23(2): 67-71.

[33] Goto M, Hosako Y, Katayama M, Yamada T. Biochemical analysis of rheumatoid synovial fluid after serial intra-articular injection of high molecular weight sodium hyaluronate. Int J Clin Pharmacol Res 1993; 3: 161-6.

[34] Gomis A, Miralles A, Schmidt RF, Belmonte C. Intra-articular injections of hyaluronan solutions of different elastoviscosity reduce nociceptive nerve activity in a model of osteoarthritic knee joint of the guinea pig. Osteoarthritis Cartilage 2009; 17(6): 798-804.

[35] Masuko-Hongo K, Sato T, Nishioka K. Chemokines differentially induce matrix metalloproteinase-3 and prostaglandin E2 in human articular chondrocytes. Clin Exp Rheumatol 2005; 23(1): 57-62.

[36] Strauss E, Schachter A, Frenkel S, Rosen J. The efficacy of intra-articular hyaluronan injection after the microfracture technique for the treatment of articular cartilage lesions. Am J Sports Med 2009; 37(4): 720-6.